Non-nucleoside reverse transcriptase inhibitors: a review.
Non-nucleoside reverse transcriptase inhibitors form the backbone of antiretroviral treatment for many HIV-infected individuals. The tolerability, pill burden and efficacy associated with this class of agents make them a frequent choice for first-line therapy. Here we review nevirapine and efavirenz in terms of efficacy, resistance and toxicity, focusing particularly on the use of nevirapine to prevent mother-to-child transmission in developing countries.
Waters
L
L
Department of HIV/GU Medicine, Chelsea & Westminster Hospital, London, UK.
John
L
L
Nelson
M
M
D023241:Antiretroviral Therapy, Highly Active; D002318:Cardiovascular Diseases / Q000209:etiology; D056486:Chemical and Drug Induced Liver Injury; D003875:Drug Eruptions / Q000209:etiology; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D039682:HIV-Associated Lipodystrophy Syndrome / Q000209:etiology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D017060:Patient Satisfaction; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D018894:Reverse Transcriptase Inhibitors